HK1069537A1 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect - Google Patents

Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Info

Publication number
HK1069537A1
HK1069537A1 HK05102146.4A HK05102146A HK1069537A1 HK 1069537 A1 HK1069537 A1 HK 1069537A1 HK 05102146 A HK05102146 A HK 05102146A HK 1069537 A1 HK1069537 A1 HK 1069537A1
Authority
HK
Hong Kong
Prior art keywords
devoid
endowed
derivatives
antiangiogenic activity
heparanase inhibitors
Prior art date
Application number
HK05102146.4A
Other languages
English (en)
Inventor
Benito Casu
Giangiacomo Torri
Annamaria Naggi
Giuseppe Giannini
Claudio Pisano
Sergio Penco
Original Assignee
Sigma Tau Res Switzerland Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Res Switzerland Sa filed Critical Sigma Tau Res Switzerland Sa
Publication of HK1069537A1 publication Critical patent/HK1069537A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
HK05102146.4A 2001-09-12 2005-03-11 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect HK1069537A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2001/000472 WO2003022291A1 (en) 2001-09-12 2001-09-12 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Publications (1)

Publication Number Publication Date
HK1069537A1 true HK1069537A1 (en) 2005-05-27

Family

ID=11133723

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102146.4A HK1069537A1 (en) 2001-09-12 2005-03-11 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Country Status (20)

Country Link
US (1) US20050137167A1 (pt)
EP (2) EP2343077B1 (pt)
JP (1) JP2005506326A (pt)
KR (1) KR100855331B1 (pt)
CN (1) CN1547477B (pt)
AT (1) ATE511846T1 (pt)
AU (1) AU2001292231B2 (pt)
BR (1) BR0117124A (pt)
CA (1) CA2457719C (pt)
CY (2) CY1112551T1 (pt)
CZ (1) CZ307433B6 (pt)
DK (1) DK1427427T3 (pt)
ES (2) ES2367778T3 (pt)
HK (1) HK1069537A1 (pt)
HU (1) HU230385B1 (pt)
MX (1) MXPA04002217A (pt)
PT (2) PT2343077E (pt)
SI (1) SI1427427T1 (pt)
SK (1) SK288335B6 (pt)
WO (1) WO2003022291A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293275A1 (en) * 2004-03-29 2006-12-28 Toshikazu Nakamura Hgf production accelerator containing heparin-like oligosaccharide
WO2008046162A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
FI20085308A0 (fi) * 2008-04-11 2008-04-11 Polysackaridforskning I Uppsal Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2550004A4 (en) * 2010-03-12 2014-07-02 Univ Australian SUBSTITUTE THERAPY WITH HEPARAN SULFATE
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
AU2011268470B2 (en) 2010-06-17 2017-02-02 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
FR2970969B1 (fr) * 2011-01-27 2013-10-18 Sanofi Aventis Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
KR101522604B1 (ko) * 2013-03-21 2015-05-26 대한민국 곤충 글라이코자미노글라이칸 유래 헤파린 단편 및 이의 제조 방법
CA2912710C (en) * 2013-05-16 2020-06-30 Agency For Science, Technology And Research Heparan sulphates
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
ITLO20130005A1 (it) * 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
MX2017011093A (es) 2015-03-06 2018-02-19 Leadiant Biosciences S A Terapia combinada de roneparstat para mieloma multiple.
KR20190093214A (ko) 2016-12-13 2019-08-08 베타 테라퓨틱스 피티와이 리미티드 헤파라나제 억제제 및 그의 용도
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US11186603B2 (en) * 2017-03-23 2021-11-30 Victoria Link Limited Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses
EP3388439A1 (en) 2017-04-11 2018-10-17 Leadiant Biosciences SA Biotin-conjugated n-acetyl glycol split heparin
US11225531B2 (en) 2018-02-02 2022-01-18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Glycosaminoglycan derivative and preparation method therefor and use thereof
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
CN114901702B (zh) * 2019-12-27 2024-01-09 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265998A (ja) * 1986-03-10 1987-11-18 ボ−ド　オブ　リ−ジエンツ　ザ　ユニヴア−シテイ　オブ　テキサス　システム ヘパラン硫酸エンドグリコシダーゼアッセイ
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IE61758B1 (en) 1986-05-23 1994-11-30 Daiichi Seiyaku Co Use of a sulfated polysaccharide
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
IL85145A (en) 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
CZ195193A3 (en) 1992-09-25 1994-04-13 Lilly Co Eli Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5399667A (en) 1993-03-05 1995-03-21 Washington University Thrombospondin receptor binding peptides
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
AU7520394A (en) 1993-08-13 1995-03-14 Glycomed Incorporated Bridged oligosaccharides and sulfated derivatives thereof
US5739115A (en) 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
EP0722326A4 (en) 1993-10-07 1999-10-06 Glycomed Inc HIGHLY SULFATED MALTOOLIGOSSACCHARIDES WITH HEPARIN-LIKE PROPERTIES
AU2435795A (en) 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
DE19955803A1 (de) 1999-11-19 2001-05-23 Knoll Ag Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
AU3078800A (en) * 2000-01-25 2001-08-07 Nippon Eisei Center Co., Ltd. Earthquake-proofing reinforcing metal fitting

Also Published As

Publication number Publication date
CZ2004255A3 (cs) 2004-11-10
CY1114544T1 (el) 2016-10-05
EP1427427B1 (en) 2011-06-08
HUP0401693A3 (en) 2009-06-29
CN1547477A (zh) 2004-11-17
SK288335B6 (sk) 2016-02-02
PT2343077E (pt) 2013-08-29
CZ307433B6 (cs) 2018-08-22
CN1547477B (zh) 2010-12-22
SI1427427T1 (sl) 2011-10-28
JP2005506326A (ja) 2005-03-03
WO2003022291A1 (en) 2003-03-20
CA2457719C (en) 2012-01-03
CA2457719A1 (en) 2003-03-20
KR100855331B1 (ko) 2008-09-04
ATE511846T1 (de) 2011-06-15
MXPA04002217A (es) 2004-07-08
AU2001292231B2 (en) 2008-06-05
SK1602004A3 (en) 2004-08-03
HUP0401693A2 (hu) 2004-12-28
EP1427427A1 (en) 2004-06-16
ES2431362T3 (es) 2013-11-26
ES2367778T3 (es) 2011-11-08
EP2343077A1 (en) 2011-07-13
BR0117124A (pt) 2004-09-28
PT1427427E (pt) 2011-09-13
DK1427427T3 (da) 2011-09-19
US20050137167A1 (en) 2005-06-23
KR20040048404A (ko) 2004-06-09
HU230385B1 (hu) 2016-03-29
CY1112551T1 (el) 2016-02-10
EP2343077B1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
HK1069537A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
HK1051867A1 (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
WO2008024892A3 (en) Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors
IS6733A (is) Fjölsykrur með virkni gegn blóðtappa, sem samanstanda af, að minnsta kosti, samgildu tengi við bíótín eða bíótínafleiðu
AU2003263925A1 (en) Multi-lumen vascular grafts having improved self-sealing properties
HK1080065A1 (zh) 具有抗血管生成和抗癌症活性的磺胺藥物
AU2003297755A8 (en) Variable characteristic venous access catheter
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
CA2440072A1 (en) Pocket door slide
IL173905A0 (en) Malonamide derivatives blocking the activity of gama-secretase
PL377864A1 (pl) Pochodne 1-N-(fenylo)-2-N-(fenylo)pirazolidyno-1,2-dikarboksyamidowe jako inhibitory czynnika koagulacyjnego Xa do leczenia zakrzepic
EP1810693A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
MXPA05010414A (es) Uso de clusterina para el tratamiento y/o prevencion de enfermedades neurologicas perifericas.
EP1667976A4 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
WO2006044155A3 (en) Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
WO2005005382A3 (en) Compounds, compositions and methods
WO2003092669A3 (en) Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
PL368813A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
EP1734948A4 (en) THREE SUBSTITUTE 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDROPYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDROPYRAN-3-OL ANALOGS AND NOVEL DERIVATIVES DISUBSTITUTED PYRANES 3.6
PL356170A1 (en) Diazocin-dione derivatives and their use s tryptase inhibitors
SI2343077T1 (sl) Derivati popolnoma N-desulfatiranih glikozaminoglikanov kot heparanazni inhibitorji z antiangiogeno aktivnostjo in brez antikoagulacijskega učinka
AU2003284463A1 (en) Protector for indwelling needle having wings
DE60334533D1 (de) Gewebe-engineering
MXPA05012758A (es) Derivados de captopril.
SI1268558T1 (sl) Delno desulfatizirani derivati glikozaminglikata, ki imajo antiangiogeno delovanje in nimajo antikoagulacijskega delovanja

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190906